Adicet Bio, Inc. Common Stock (ACET)
Adicet Bio, Inc. is a biotechnology company focused on the development of allogeneic cell therapies for cancer and other diseases. Leveraging innovative immune cell engineering technologies, Adicet aims to create off-the-shelf, highly effective treatments that harness the body's immune system to target and destroy disease cells.
Company News
ACET ($ACT), a blockchain-powered DeFi platform, has partnered with the Royal Office of H.H. Sheikh Ahmed Bin Faisal Al-Qassimi to drive blockchain adoption and financial innovation in the UAE, including integrating ACET ($ACT) into a $3.9 billion casino resort project.
Adicet Bio (ACET) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Shares of JetBlue Airways Corporation (NASDAQ: JBLU) fell sharply during Tuesday’s session. JetBlue’s President & COO Joanna Geraghty will succeed Robin Hayes as CEO, effective Feb. 12, 2024. B of A Securities analyst Andrew Didora downgrades JetBlue Airways from Neutral to Underperform and lowered the price target from $6 to $3. JetBlue Airw...
Michael Hartnett said there will be a point to fade the S&P 500 rally. But not yet.
These companies' share prices could rise in the short term, but their long-term opportunities are even better.
